Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139408 | 0.89 | IRAK4 (0.67) | IRAK4NPC1RAB9AMAPK1TLR7 | |
| SCHEMBL10054633 | 0.87 | TLR7 (0.47) | IRAK4HPGDLMNAPOLBNPC1 | |
| SCHEMBL2141469 | 0.84 | RAB9A (0.46) | IRAK4LMNAMEN1KMT2APOLB | |
| SCHEMBL2142275 | 0.84 | RAB9A (0.46) | IRAK4LMNAPOLBNPC1RAB9A | |
| SCHEMBL4238040 | 0.84 | CHEK1 (0.52) | IRAK4LMNAPOLBNPC1RAB9A | |
| SCHEMBL2139271 | 0.84 | LMNA (0.57) | IRAK4HPGDLMNAMAPTMEN1 | |
| SCHEMBL2138509 | 0.84 | CHEK1 (0.59) | IRAK4HPGDLMNAMAPTMEN1 | |
| SCHEMBL2139382 | 0.83 | KDM4E (0.55) | IRAK4LMNAMAPTPOLBNPC1 | |
| SCHEMBL1830298 | 0.82 | RAB9A (0.44) | IRAK4LMNAMAPTMEN1KMT2A | |
| SCHEMBL2141593 | 0.82 | IRAK4 (0.46) | IRAK4LMNAPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | claimed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | claimed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | claimed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | claimed |
| JP-5348704-B2 | — | — | 2013-11-20 | — | — | JP | disclosed |
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | disclosed |
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-2231652-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009074246-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CNR2, CYP11B2, CYP2C19 | IRAK4 788/4885HPGD 287/4885LMNA 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.